Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864926 · ClinicalTrials.gov registry record · Phase 4
Envarsus in Delayed Graft Function (E-DGF)
A Phase 4 study of Delayed Graft Function, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03864926 is a Phase 4 study of Delayed Graft Function that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 100 participants, below the 358-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03864926, a Phase 4 study of Delayed Graft Function, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus. It is expected that patients with DGF on Envarsus XR will have more stable tacrolimus levels and facilitate early recover from DGF compared to immediate release tacrolimus.
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Envarsus XR
Study Locations (1)
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03864926
The ClinicalTrials.gov registry entry for NCT03864926 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (72% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delayed Graft Function appearing as the primary indexed condition, and to 2 interventions - of which Tacrolimus is the first listed.
NCT03864926 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03864926 about?
NCT03864926 is a clinical study titled "Envarsus in Delayed Graft Function (E-DGF)". Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus. It is expected that patients with DGF on Envarsus XR will have more stable tacrolimu...
What is the current status of trial NCT03864926?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2019-03-18. Estimated completion is 2022-07-22.
What conditions does trial NCT03864926 study?
This clinical trial studies the following conditions: Delayed Graft Function.
What interventions are being tested in trial NCT03864926?
The interventions under investigation include: Tacrolimus (DRUG), Envarsus XR (DRUG).
Who is sponsoring clinical trial NCT03864926?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03864926 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Graft Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
COMPLETED · Phase 4
-
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
RECRUITING · Phase 1
-
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
RECRUITING · Phase 3
-
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
ACTIVE NOT RECRUITING · Phase 2
-
Deceased Organ Donor Interventions to Protect Kidney Graft Function
COMPLETED · NA
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.